Rigel Assumes Development Responsibility for Inhaled Asthma Therapy – PR Newswire (press release)

Rigel Assumes Development Responsibility for Inhaled Asthma Therapy
PR Newswire (press release)
SOUTH SAN FRANCISCO, Calif., May 6, 2011 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.